All In Biotech

Drug Trial Radar · NCT05633667

Study of Novel Treatment Combinations in Patients With Lung Cancer

A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

192

Actual

Start

Mar 16, 2023

Primary completion

Sep 2029

Study completion Sep 2029

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Arcus Biosciences, Inc.
First posted
Dec 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC. The primary objectives of this study are: Substudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Substudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.

Conditions

  • Lung Cancer
  • Advanced or Metastatic Non-Small-Cell Lung Cancer
  • Resectable Non-Small-Cell Lung Cancer

Interventions

  • Zimberelimab (ZIM)Drug

    Administered intravenously

  • Domvanalimab (DOM)Drug

    Administered intravenously

  • Sacituzumab govitecan-hziy (SG)Drug

    Administered intravenously

  • Etrumadenant (ETRUMA)Drug

    Administered orally

  • CarboplatinDrug

    Administered intravenously

  • CisplatinDrug

    Administered intravenously

  • PemetrexedDrug

    Administered intravenously

  • PaclitaxelDrug

    Administered intravenously

  • Nab-paclitaxelDrug

    Administered intravenously

  • DocetaxelDrug

    Administered intravenously

  • NivolumabDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Substudies 01 and 02: Objective Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Up to 5 years
  2. Substudy 03: Complete Pathological Response (pCR) RateTime frame: Up to 5 years

Locations

89 sites in 8 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates,Substudy-02

    Tucson, Arizona

  • Fort Wayne Medical Oncology and Hematology, Inc.,Substudy-03

    Fort Wayne, Indiana

  • Baptist Health Lexington,Substudy-03

    Lexington, Kentucky

  • Washington University School of Medicine - Siteman Cancer Center,Substudy-01

    St Louis, Missouri

  • Washington University School of Medicine - Siteman Cancer Center,Substudy-02

    St Louis, Missouri

  • Washington University School of Medicine - Siteman Cancer Center,Substudy-03

    St Louis, Missouri

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri

  • Oncology Hematology Care Clinical Trials, LLC,Substudy-01

    Cincinnati, Ohio

  • Oncology Hematology Care Clinical Trials, LLC,Substudy-02

    Cincinnati, Ohio

  • Oncology Associates of Oregon, PC,Substudy-01

    Eugene, Oregon

  • Oncology Associates of Oregon, PC,Substudy-02

    Eugene, Oregon

  • Fundação Pio XII - Hospital de Amor,Substudy-01

    Barretos, Brazil

  • Centro Gaúcho Integrado de Oncologia Hematologia, Ensino e Pesquisa Ltda./Hospital Mãe de Deus,Substudy-03

    Porto Alegre, Brazil

  • Hospital Mae de Deus,Substudy-01

    Porto Alegre, Brazil

  • Hospital Mae de Deus

    Porto Alegre, Brazil

  • Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-01

    Porto Alegre, Brazil

  • Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03

    Porto Alegre, Brazil

  • BP-A Beneficencia Portuguesa De Sao Paulo,Substudy-01

    São Paulo, Brazil

  • Fundação Antonio Prudente - Hospital do Câncer AC Camargo,Substudy-01

    São Paulo, Brazil

  • Fundação Antonio Prudente/A.C. Camargo Cancer Center,Substudy-03

    São Paulo, Brazil

  • Real e Benemérita Associação Portuguesa de Beneficência/Hospital Beneficência Portuguesa de São Paulo (Hospital BP),Substudy-03

    São Paulo, Brazil

  • Queen Mary Hospital,Substudy-01

    Hong Kong, Hong Kong

  • Queen Mary Hospital,Substudy-02

    Hong Kong, Hong Kong

  • Queen Elizabeth Hospital,Substudy-01

    Hong Kong, Hong Kong

  • Queen Elizabeth Hospital,Substudy-02

    Hong Kong, Hong Kong

  • Prince of Wales Hospital,Substudy-01

    New Territories, Hong Kong

  • Prince of Wales Hospital,Substudy-02

    New Territories, Hong Kong

  • Rambam Health Care Campus,Substudy-01

    Haifa, Israel

  • Rambam Health Care Campus,Substudy-02

    Haifa, Israel

  • Rambam Health Care Campus,Substudy-03

    Haifa, Israel

  • Shaare Zedek Medical Center,Substudy-01

    Jerusalem, Israel

  • Shaare Zedek Medical Center,Substudy-02

    Jerusalem, Israel

  • Shaare Zedek Medical Center,Substudy-03

    Jerusalem, Israel

  • Hadassah Medical Center,Substudy-01

    Jerusalem, Israel

  • Hadassah University Medical Center,Substudy-03

    Jerusalem, Israel

  • Tel Aviv Sourasky Medical Center,Substudy-01

    Tel Aviv, Israel

  • Tel Aviv Sourasky Medical Center,Substudy-02

    Tel Aviv, Israel

  • Tel-Aviv Sourasky Medical Center,Substudy-03

    Tel Aviv, Israel

  • Chungbuk National University Hospital,Substudy-01

    Cheongju-si, South Korea

  • Chungbuk National University Hospital,Substudy-02

    Cheongju-si, South Korea

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.